| 65643 | |
| Topoisomerase enzymes are involved in the restructuring of DNA during synthesis to give other enzymes easy access to copy the two strands. DNA synthesis is an important step, occurring only when a cell is proliferating. Continual proliferation is a key characteristic of cancerous cells, and thus, topoisomerases are ideal targets for cancer therapeutics. Scientists are currently attempting to synthesize topoisomerase inhibitors that have differing target sites to more effectively eliminate cancer cells. Finding novel binding sites for inhibitors becomes paramount for overcoming drug resistance. Scientists at Purdue University have developed novel compounds to inhibit Topoisomerase I that are intended to cease DNA synthesis and cause cell death. These inhibitors will be used as the primary treatment or in a synergistic manner to treat proliferating tumors. This innovation provides a novel, efficient, and scalable, synthetic route to these compounds that possess and express Top I inhibition and cytotoxicity. Advantages: -Anticancer properties -Cytotoxicity to a variety of cancers -Topoisomerase 1 is a proven target for cancer therapy Potential Applications: -Medical/Healthcare -Cancer Treatment -Pharmaceuticals -Drug Development |
|
|
|
|
Feb 14, 2013
NATL-Patent
United States
9,073,920
Jul 7, 2015
Aug 17, 2011
PCT-Patent
WO
(None)
(None)
Aug 17, 2010
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |